Long-term outcome of patients with ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab
Auteur(s) :
Laharie, David [Auteur]
Université de Bordeaux [UB]
Bourreille, Arnaud [Auteur]
Institut des Maladies de l'Appareil Digestif
Branche, Julien [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Allez, Matthieu [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Bouhnik, Yoram [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Filippi, Jerome [Auteur]
Zerbib, Frank [Auteur]
Université de Bordeaux [UB]
Savoye, Guillaume [Auteur]
Université de Rouen Normandie [UNIROUEN]
Vuitton, Lucine [Auteur]
Moreau, Jacques [Auteur]
Amiot, Aurelien [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Cosnes, Jacques [Auteur]
Ricart, Elena [Auteur]
Dewit, Olivier [Auteur]
Lopez-Sanroman, Antonio [Auteur]
Fumery, Mathurin [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Carbonnel, Franck [Auteur]
Université Paris-Sud - Paris 11 - Faculté de médecine [UP11 UFR Médecine]
Bommelaer, Gilles [Auteur]
Coffin, Benoit [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Roblin, Xavier [Auteur]
Van Assche, Gert [Auteur]
Esteve, M [Auteur]
Farkkila, Martti [Auteur]
Gisbert J., P [Auteur]
Marteau, Philippe [Auteur]
Nahon, Stephane [Auteur]
De Vos, Martine [Auteur]
Lambert, Jerome [Auteur]
Mary, Jean-Yves [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Louis, Edouard [Auteur]
Université de Bordeaux [UB]
Bourreille, Arnaud [Auteur]
Institut des Maladies de l'Appareil Digestif
Branche, Julien [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Allez, Matthieu [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Bouhnik, Yoram [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Filippi, Jerome [Auteur]
Zerbib, Frank [Auteur]
Université de Bordeaux [UB]
Savoye, Guillaume [Auteur]
Université de Rouen Normandie [UNIROUEN]
Vuitton, Lucine [Auteur]
Moreau, Jacques [Auteur]
Amiot, Aurelien [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Cosnes, Jacques [Auteur]
Ricart, Elena [Auteur]
Dewit, Olivier [Auteur]
Lopez-Sanroman, Antonio [Auteur]
Fumery, Mathurin [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Carbonnel, Franck [Auteur]
Université Paris-Sud - Paris 11 - Faculté de médecine [UP11 UFR Médecine]
Bommelaer, Gilles [Auteur]
Coffin, Benoit [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Roblin, Xavier [Auteur]
Van Assche, Gert [Auteur]
Esteve, M [Auteur]
Farkkila, Martti [Auteur]
Gisbert J., P [Auteur]
Marteau, Philippe [Auteur]
Nahon, Stephane [Auteur]
De Vos, Martine [Auteur]
Lambert, Jerome [Auteur]
Mary, Jean-Yves [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Louis, Edouard [Auteur]
Titre de la revue :
Gut
Nom court de la revue :
Gut
Numéro :
67
Pagination :
237-243
Date de publication :
2018-04-20
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Objective : Ciclosporin and infliximab have demonstrated short-term similar efficacy as second-line therapies in patients with acute severe UC (ASUC) refractory to intravenous steroids. The aim of this study was to assess ...
Lire la suite >Objective : Ciclosporin and infliximab have demonstrated short-term similar efficacy as second-line therapies in patients with acute severe UC (ASUC) refractory to intravenous steroids. The aim of this study was to assess long-term outcome of patients included in a randomised trial comparing ciclosporin and infliximab. Design : Between 2007 and 2010, 115 patients with steroid-refractory ASUC were randomised in 29 European centres to receive ciclosporin or infliximab in association with azathioprine. Patients were followed until death or last news up to January 2015. Colectomy-free survival rates at 1 and 5 years and changes in therapy were estimated through Kaplan-Meier method and compared between initial treatment groups through log-rank test. Results : After a median follow-up of 5.4 years, colectomy-free survival rates (95% CI) at 1 and 5 years were, respectively, 70.9% (59.2% to 82.6%) and 61.5% (48.7% to 74.2%) in patients who received ciclosporin and 69.1% (56.9% to 81.3%) and 65.1% (52.4% to 77.8%) in those who received infliximab (p=0.97). Cumulative incidence of first infliximab use at 1 and 5 years in patients initially treated with ciclosporin was, respectively, 45.7% (32.6% to 57.9%) and 57.1% (43.0% to 69.0%). Only four patients from the infliximab group were subsequently switched to ciclosporin. Three patients died during the follow-up, none directly related to UC or its treatment. Conclusions : In this cohort of patients with steroid-refractory ASUC initially treated by ciclosporin or infliximab, long-term colectomy-free survival was independent from initial treatment. These long-term results further confirm a similar efficacy and good safety profiles of both drugs and do not favour one drug over the other.Lire moins >
Lire la suite >Objective : Ciclosporin and infliximab have demonstrated short-term similar efficacy as second-line therapies in patients with acute severe UC (ASUC) refractory to intravenous steroids. The aim of this study was to assess long-term outcome of patients included in a randomised trial comparing ciclosporin and infliximab. Design : Between 2007 and 2010, 115 patients with steroid-refractory ASUC were randomised in 29 European centres to receive ciclosporin or infliximab in association with azathioprine. Patients were followed until death or last news up to January 2015. Colectomy-free survival rates at 1 and 5 years and changes in therapy were estimated through Kaplan-Meier method and compared between initial treatment groups through log-rank test. Results : After a median follow-up of 5.4 years, colectomy-free survival rates (95% CI) at 1 and 5 years were, respectively, 70.9% (59.2% to 82.6%) and 61.5% (48.7% to 74.2%) in patients who received ciclosporin and 69.1% (56.9% to 81.3%) and 65.1% (52.4% to 77.8%) in those who received infliximab (p=0.97). Cumulative incidence of first infliximab use at 1 and 5 years in patients initially treated with ciclosporin was, respectively, 45.7% (32.6% to 57.9%) and 57.1% (43.0% to 69.0%). Only four patients from the infliximab group were subsequently switched to ciclosporin. Three patients died during the follow-up, none directly related to UC or its treatment. Conclusions : In this cohort of patients with steroid-refractory ASUC initially treated by ciclosporin or infliximab, long-term colectomy-free survival was independent from initial treatment. These long-term results further confirm a similar efficacy and good safety profiles of both drugs and do not favour one drug over the other.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Équipe(s) de recherche :
Inflammatory digestive disease : pathophysiology and therapeutic targets developement
Date de dépôt :
2019-03-01T14:26:06Z
2024-04-22T08:02:53Z
2024-04-22T08:02:53Z